Why 2023 was the year of un­so­licit­ed ac­qui­si­tion bids — and why next year like­ly won’t be

In a year with a no­table num­ber of un­so­licit­ed ac­qui­si­tion bids, one com­pa­ny stood out as 2023’s se­r­i­al bid­der.

Tang Cap­i­tal Man­age­ment — through its shell Con­cen­tra — made five un­so­licit­ed of­fers through­out the year for Atea Phar­ma­ceu­ti­cals, Jounce Ther­a­peu­tics, Lian­Bio, Rain On­col­o­gy and The­seus Phar­ma­ceu­ti­cals. The in­vest­ment group, based out of Cal­i­for­nia and led by Kevin Tang, is a mi­nor­i­ty share­hold­er in all of these tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER